Cagrilintide and Tesamorelin Interaction

Synergistic
Mechanism-based 60% confidence

Cagrilintide and Tesamorelin have a synergistic interaction with 60% confidence. Cagrilintide helps counteract the insulin-disrupting effects of Tesamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects. Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

Cagrilintide

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

Half-life: ~7 days (159-195 hours) Typical dose: 2.4mg weekly (after escalation) weight loss, metabolic
amylin receptor cardiotoxicinsulin sensitizing
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low
Pituitary
low

Frequently Asked Questions

Can I take Cagrilintide with Tesamorelin?

Yes, Cagrilintide and Tesamorelin can generally be taken together. Cagrilintide helps counteract the insulin-disrupting effects of Tesamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.

Is Cagrilintide and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between Cagrilintide and Tesamorelin?

Cagrilintide helps counteract the insulin-disrupting effects of Tesamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects. This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.

How should I time Cagrilintide and Tesamorelin?

Cagrilintide has a half-life of ~7 days (159-195 hours) and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Cagrilintide vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.